Related Experiment Videos
[Beta-blocking treatment (author's transl)].
Klinische Monatsblatter Fur Augenheilkunde
|November 1, 1981
Summary
Topical timolol 0.5% eye drops can cause systemic effects in open-angle glaucoma patients, particularly those with chronic obstructive pulmonary disease or other beta-blocker contraindications.
Area of Science:
- Ophthalmology
- Cardiology
- Pulmonology
Context:
- Open-angle glaucoma management often involves topical medications.
- Systemic absorption of topical ocular drugs can lead to adverse effects.
- Patients with pre-existing cardiovascular or pulmonary conditions may be at higher risk.
Purpose:
- To investigate the systemic effects of topical timolol 0.5% in open-angle glaucoma patients.
- To assess the extent of systemic absorption and resulting adverse events.
- To evaluate risks in patients with contraindications to systemic beta-blockers.
Summary:
- Twenty-six open-angle glaucoma patients with contraindications for systemic beta-blockers (bradycardia, cardiac insufficiency, COPD) received topical timolol 0.5%.
- Systemic effects, including cardiovascular and pulmonary adverse events, were observed.
- Patients with chronic obstructive pulmonary disease (COPD) experienced particularly marked effects.
Impact:
- Highlights the potential for systemic absorption and adverse effects from topical timolol, even in patients with contraindications.
- Underscores the need for careful monitoring of patients with pre-existing conditions receiving topical beta-blockers.
- Informs clinical practice regarding the safe use of topical timolol in glaucoma management.